Liraglutide's Impact on Knee Inflammation in Obese Osteoarthritis Patients

Knee osteoarthritis (KOA) is a debilitating joint disease, often exacerbated by obesity, which contributes to both mechanical stress and systemic inflammation. While weight loss is a primary recommendation, the specific mechanisms by which weight-loss medications might alleviate KOA symptoms and inflammation are not fully understood. This Phase 4 clinical trial aimed to investigate the impact of liraglutide treatment on knee inflammation and structural changes in obese patients with KOA using advanced imaging techniques.

As this record describes a completed clinical trial design (NCT02928679) and not its published results, specific data on findings are not available here. However, the study was designed to assess the effects of liraglutide 3 mg on various markers of knee health. The primary objective was to evaluate changes in knee inflammation and cartilage integrity using advanced multi-parametric imaging. The researchers aimed to determine if liraglutide 3 mg treatment could lead to a significant reduction in inflammatory markers within the knee joint and potentially mitigate cartilage degradation in obese patients with knee osteoarthritis. Secondary objectives likely included assessing changes in pain, physical function, and body weight, which are common outcomes in osteoarthritis and obesity studies. The detailed imaging data would have provided insights into the structural impact of liraglutide beyond simple weight loss.